Bristol-Myers Squibb Company · BMY
As of the latest run, Bristol-Myers Squibb Company (BMY) scores 69/100 overall — a broadly solid profile. Its strongest dimension: profitability (100/100); the one that most warrants attention: valuation (44/100).
Three pillars judge the company (profitability, growth, financial health), three judge the stock (valuation, momentum, risk). The score is recomputed every day from Yahoo Finance market data — the one shown above reflects today's state.
Profitability comes in at 100/100 — above-average margins and return on capital. Financial health comes in at 69/100 — a solid balance sheet, with controlled debt and sufficient liquidity. Momentum comes in at 69/100 — a well-oriented price trend.
The breakdown of each pillar — and a plain-English explanation of what it measures — is available in the full analysis, free and updated every day.
Valuation falls to 44/100 — a stretched price relative to the stock's own valuation history.
No score replaces your own judgment: Stock Analyzer is a tool for analysis and understanding, not investment advice.